Resultado de búsqueda
Hace 22 horas · FY 2024 Second Quarter Ended March 31, 2024 Financial Results. As of March 31, 2024, Sonnet had $3.8 million cash on hand and no debt. Research and development expenses were $2.2 million for the ...
Hace 22 horas · First quarter 2023 revenues were primarily due to Adocia's work under its collaboration with Tonghua Dongbao on the BioChaperone ® Combo (BC Combo) project to conduct three clinical studies in ...
Hace 22 horas · 14.05.2024 - Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteersAnnounced early ...
Hace 2 horas · First-Quarter 2024 Financial Results. Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue was $3.8 million, an 11 percent increase from the first quarter of 2023 ...
Hace 22 horas · Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive results from
Hace 2 horas · For the first quarter of 2024, selling, general and administrative expenses were approximately $3.1 million compared to $2.8 million for the first quarter of 2023. The increases were due to higher ...
Hace 5 horas · Autolus Therapeutics ( NASDAQ: AUTL) is an oncology-focused biotech trying to develop novel engineered cell therapies for blood cancers. In my last article from December 2023, I expressed optimism ...
